Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
SOPHiA GENETICS (SOPH)
NASDAQ:SOPH
SOPH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.70 - $7.37
Previous CloseN/A
Volume4.05K
Average Volume (3M)115.59K
Market Cap
$277.19M
Enterprise Value$178.19M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Mar 04, 2025EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.09
Shares Outstanding65,375,090
10 Day Avg. Volume134,470
30 Day Avg. Volume115,588
Standard Deviation0.23
R-Squared0.05
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.43
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap0.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.15
Enterprise Value/Ebitda-2.71
Forecast
1Y Price Target
$7.67Price Target Upside88.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
SOPHiA GENETICS News
PremiumCompany Announcements
SOPHiA GENETICS Q3 2024 Financial Highlights
PremiumCompany Announcements
SOPHiA GENETICS Faces Financial Challenges Amid Losses
PremiumCompany Announcements
SOPHiA GENETICS Announces Key Leadership Appointments---
Bulls Say, Bears Say
Bulls Say
Business ModelAnalyst maintains a positive view on SOPH shares due to the company's differentiated business model, large under-penetrated market, and solid balance sheet.
EarningsSOPH reported a total analysis volume of 91K, which was a 16% increase year-over-year, outperforming expectations.
Revenue ProjectionsManagement is confident that the implied fourth-quarter revenue is supported by clinical customer trends and expected improvement in pharma revenue.
Bears Say
GuidanceManagement lowered FY'24 guidance by ~17%, with 60% of the reduction in 2H coming from pharma.
Market ChallengesRevenue in the quarter was negatively impacted by macro-related headwinds in the Biopharma end market and in EMEA.
Revenue Performance2Q revenue of $15.8M fell short of MSe/cons $17.8M/17.4M.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
1.02% Mutual Funds
20.24% Other Institutional Investors
78.66% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
The estimated number of people who visited one or more of the websites owned by SOPHiA GENETICS
Desktop Users
Mobile Users
SOPH FAQ
What was SOPHiA GENETICS’s price range in the past 12 months?
SOPHiA GENETICS lowest stock price was $2.70 and its highest was $7.37 in the past 12 months.
What is SOPHiA GENETICS’s market cap?
SOPHiA GENETICS’s market cap is $277.19M.
When is SOPHiA GENETICS’s upcoming earnings report date?
SOPHiA GENETICS’s upcoming earnings report date is Mar 04, 2025 which is in 9 days.
How were SOPHiA GENETICS’s earnings last quarter?
SOPHiA GENETICS released its earnings results on Nov 05, 2024. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of -$0.222 by -$0.058.
Is SOPHiA GENETICS overvalued?
According to Wall Street analysts SOPHiA GENETICS’s price is currently Undervalued.
Does SOPHiA GENETICS pay dividends?
SOPHiA GENETICS does not currently pay dividends.
What is SOPHiA GENETICS’s EPS estimate?
SOPHiA GENETICS’s EPS estimate is -0.21.
How many shares outstanding does SOPHiA GENETICS have?
SOPHiA GENETICS has 65,375,090 shares outstanding.
What happened to SOPHiA GENETICS’s price movement after its last earnings report?
SOPHiA GENETICS reported an EPS of -$0.28 in its last earnings report, missing expectations of -$0.222. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of SOPHiA GENETICS?
Currently, no hedge funds are holding shares in SOPH
---
SOPHiA GENETICS Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.67 (88.45% Upside)
$7.67 (88.45% Upside)
Blogger Sentiment
Bullish
SOPH Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▲ 3.2%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-15.03%
12-Months-Change
Fundamentals
Return on Equity
-52.51%
Trailing 12-Months
Asset Growth
-13.72%
Trailing 12-Months
Company Description
SOPHiA GENETICS
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities.
---
SOPH Company Deck
---
SOPH Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong clinical volume growth and effective cost management, including a significant improvement in cash burn and new product adoption. However, these positives were counterbalanced by a decline in biopharma revenue and overall revenue, as well as challenges in specific regions like Latin America and Spain.Read More>---
SOPH Stock 12 Month Forecast
Average Price Target
$7.67
▲(88.45% Upside)
Technical Analysis
Best Analysts Covering SOPH
1 Year
1 Year Success Rate
5/9 ratings generated profit
1 Year Average Return
+20.54%
reiterated a buy rating 7 months ago
Copying Mark Massaro's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +20.54% per trade.
---